Vitiligo Treatment Through Targeted Tissue-Resident Memory T-Cell Depletion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Vitiligo, an autoimmune disease characterized by patchy depigmentation, is challenging to treat due to the persistence of autoimmune memory in the skin, leading to rapid relapse after conventional treatments are discontinued, and there are currently no FDA-approved treatments.
Innovation Solution
Targeting tissue resident memory T cells (Trm) with inhibitors of Sphingosine-1-phosphate receptor 1 (SIP1), Interleukin 15 (IL-15), or the IL-15 receptor, such as through small molecule inhibitors, antibodies, or inhibitory nucleic acids, to deplete or inhibit their function, thereby treating vitiligo and other autoimmune diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for vitiligo, then initial improvement may be achieved, but rapid relapse occurs after treatment discontinuation due to persistent autoimmune memory
Solution Approach 1:
The patent applies preliminary action by targeting and depleting tissue-resident memory T cells (Trm) before they can initiate disease relapse. By administering anti-CD160 antibodies or CD160-directed cytotoxic cells in advance, the treatment eliminates the reservoir of autoreactive memory cells that would otherwise cause rapid relapse after conventional therapy discontinuation, thereby extending durable remission
Solution Approach 2:
The patent extracts and removes the harmful component (autoreactive Trm cells) from the system.通过使用anti-CD160 antibodies或CD160-directed cytotoxic cells, the treatment specifically identifies and eliminates tissue-resident memory T cells that mediate vitiligo relapse, separating these pathogenic cells from the broader immune system to achieve durable disease control
2Reliability
If tissue resident memory T cells are targeted to prevent relapse, then durable remission is achieved, but treatment complexity increases due to need for specific inhibitors
Solution Approach 1:
The patent uses CD160 as an intermediary marker to target Trm cells. By conjugating anti-CD160 antibodies with cytotoxic payloads or using CD160-directed cytotoxic cells, the treatment creates a targeted delivery system that specifically eliminates autoreactive Trm cells while sparing other immune cells, thereby achieving durable remission with controlled specificity
Solution Approach 2:
The patent changes the therapeutic parameter from broad immunosuppression to targeted Trm cell depletion. By shifting the mechanism of action to specifically target CD160+ Trm cells, the treatment achieves durable remission with potentially lower overall immunosuppression requirements, modifying the key parameter of immune cell targeting specificity
Data Source
AI summary
Methods of diagnosing and treating vitiligo.